Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

BGP-15

🥰Excellent
Catalog No. T3649Cas No. 66611-37-8
Alias BGP15 2hydrobromide, BGP-15 2HCl

BGP-15 (BGP-15 2HCl) is a PARP inhibitor with protecting effect after ischemia-reperfusion injury.

BGP-15

BGP-15

🥰Excellent
Purity: 99.89%
Catalog No. T3649Alias BGP15 2hydrobromide, BGP-15 2HClCas No. 66611-37-8
BGP-15 (BGP-15 2HCl) is a PARP inhibitor with protecting effect after ischemia-reperfusion injury.
Pack SizePriceAvailabilityQuantity
5 mg$29In Stock
10 mg$47In Stock
25 mg$95In Stock
50 mg$158In Stock
100 mg$257In Stock
200 mg$378In Stock
1 mL x 10 mM (in DMSO)$32In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "BGP-15"

Select Batch
Purity:99.89%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
BGP-15 (BGP-15 2HCl) is a PARP inhibitor with protecting effect after ischemia-reperfusion injury.
Targets&IC50
PARP:120 μM
In vitro
In two mouse models developed to exhibit heart failure and atrial fibrillation, BGP-15 has been shown to enhance cardiac function and reduce arrhythmia [2]. Pretreatment with BGP-15 (100-200 mg/kg, p.o.) before cisplatin administration can either prevent or significantly inhibit the development of cisplatin-induced acute renal failure. BGP-15 demonstrates significant antioxidant effects on the kidneys in the context of cisplatin-induced nephrotoxicity. Despite BGP-15's ability to protect the kidneys from nephrotoxic effects, it does not diminish the antitumor efficacy of cytostatic agents. In the kidneys, BGP-15 inhibits cisplatin-induced poly(ADP-ribose) polymerization [1].
In vivo
BGP-15 acts as an in vitro inducer of HSP72, effective only when co-treated with heat shock, without affecting HSP90 levels. At a concentration of 200 μM, BGP-15 mitigates the depletion of high-energy phosphate compounds and prevents oxidative damage induced by imatinib mesylate. This is achieved by promoting the phosphorylation of Akt and GSK-3beta, and inhibiting the activation of p38 MAPK and JNK, thereby altering the signaling effects of imatinib mesylate. Moreover, BGP-15 significantly inhibits the activation of p38 and JNK, enzymes known to facilitate cell death and inflammatory responses in ex vivo perfused hearts.
Cell Research
Human tumor cell lines A549, HCT-15, HCT-116, and Du-145 were maintained in RPMI 1640 medium supplemented with 10% FCS in humidified air containing 5% CO2. For in vitro cytotoxicity assays, 5×103 to 5×104 cells were plated into the wells of 96-well plates in 100 μL culture medium. On the following day, cells were exposed to BGP-15 (10, 30, 100 μg/mL) and to a series of concentrations of cisplatin either by itself or in combination. Cultures were incubated in a total volume of 200 μL for 3 more days at 37°. Samples were prepared in duplicates or triplicates. Cell growth was evaluated by MTT or SRB assays. Growth inhibition curves were calculated. (Only for Reference)
AliasBGP15 2hydrobromide, BGP-15 2HCl
Chemical Properties
Molecular Weight351.27
FormulaC14H24Cl2N4O2
Cas No.66611-37-8
SmilesCl.Cl.N\C(=N/OCC(O)CN1CCCCC1)c1cccnc1
Relative Density.no data available
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
H2O: 64 mg/mL (182.2 mM)
Ethanol: 65 mg/mL (185 mM)
DMSO: 65 mg/mL (185 mM)
Solution Preparation Table
H2O/Ethanol/DMSO
1mg5mg10mg50mg
1 mM2.8468 mL14.2341 mL28.4681 mL142.3406 mL
5 mM0.5694 mL2.8468 mL5.6936 mL28.4681 mL
10 mM0.2847 mL1.4234 mL2.8468 mL14.2341 mL
20 mM0.1423 mL0.7117 mL1.4234 mL7.1170 mL
50 mM0.0569 mL0.2847 mL0.5694 mL2.8468 mL
100 mM0.0285 mL0.1423 mL0.2847 mL1.4234 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy BGP-15 | purchase BGP-15 | BGP-15 cost | order BGP-15 | BGP-15 chemical structure | BGP-15 in vivo | BGP-15 in vitro | BGP-15 formula | BGP-15 molecular weight